ArticleDiscover oncology2026
Clinical characterization and targeted genetic mutation profiling of autoimmune disease-associated B-cell lymphoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated autoimmune diseases (ADs) clinical characteristics, their association with B-cell lymphoma (BCL), and related frequent genetic mutations.
methodsA retrospective review of 2,040 BCL patients at Henan Provincial People’s Hospital (2016–2022) identified 98 with concurrent ADs.
resultsHashimoto’s thyroiditis was the most common AD identified, followed by Sjögren’s syndrome, rheumatoid arthritis, and autoimmune hemolytic anemia. The median interval from initial AD diagnosis to BCL development was 9 years, varying significantly across AD subtypes (P = 0.038). Marginal zone lymphoma (MZL) were more frequent in patients with Sjögren’s syndrome (P < 0.001) and inflammatory bowel disease (P = 0.03). BCL with concurrent ADs occurred more frequently in female patients (P = 0.009). These patients also exhibited higher levels of β2-microglobulin ≥ 2.5 mg/L (P = 0.001), demonstrated more frequent bone marrow infiltration (P = 0.017), and demonstrated a higher prevalence of gastrointestinal tract involvement (P = 0.033). However, the presence of concurrent ADs did not significantly affect overall BCL patient prognosis (P = 0.188). The next-generation sequencing (NGS) results indicate that the top four mutated genes identified in the AD-associated DLBCL cohort are B2M, BIRC3, RB1, and PLCG2. In the DLBCL cohort, the predominant mutated genes are KMT2C, EGR1, BCL2, and DDX3X.
conclusionsAD-associated BCL predominantly affects females, with more common bone marrow involvement. Hashimoto’s thyroiditis is the most prevalent AD type, with a 9-year median interval from AD diagnosis to BCL development. Concurrent ADs do not significantly impact BCL survival. Mutations in BIRC3, RB1, B2M, PLCG2, and EP300 are present in patients with AD-associated DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.